In the News

COLUMBIA, S.C. (April 2, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, launched two new unit dose syringe products, Neostigmine Methylsulfate Injection 3 mg/3 mL (1 mg/mL) and Neostigmine Methylsulfate Injection 5 mg/5 mL (1mg/mL). These are part of a 12-product rollout expected from Ritedose over the next six months for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

COLUMBIA, S.C. (March 25, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Succinylcholine Chloride Injection 200 mg/10 mL (20 mg/mL). It is the first of 12 Ritedose products expected to hit the market over the next six months for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

“The Ritedose Corporation is honored and proud to have been selected as a subcontractor to ApiJect for the production of single-dose prefilled syringes intended for administering COVID-19 vaccines. This is a direct result of the commitment demonstrated each day by the talented and dedicated people who work here.